Not Signed In -
Biopsy of the Kidneys |
|
|
Clinical Trial: Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Disease
This study is currently recruiting patients.
Purpose
Selected patients suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI.
| Condition |
|---|
| Neoplasm |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy
Study Type: Observational
Study Design: Natural History
Expected Total Enrollment: 1000
Study start: July 10, 1997
Selected patients suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI and at the National Naval Medical Center. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI. Samples will also be collected on the NNMC-IRB approved protocol, "Collection of Serum and Tissue Samples from patients with biopsy proved or suspected malignant disease", NNMC B99-062, from the National Navy Medical Center.
Eligibility
Genders Eligible for Study: Both
Criteria
Patients suspected of having, or with biopsy proof of malignant disease are eligible.
Patients must be able to provide informed consent.
Location and Contact Information
Maryland
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States; Recruiting
More Information
Detailed Web Page
Publications
Evans RM, Laskin JD, Hakala MT. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 1980 Nov;40(11):4113-22. No abstract available.
Calabro-Jones PM, Byfield JE, Ward JF, Sharp TR. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res. 1982 Nov;42(11):4413-20. No abstract available.
Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992 Apr 1;52(7):1855-64.
Record last reviewed: June 1, 2004
Last Updated: November 23, 2004
Record first received: November 14, 2001
ClinicalTrials.gov Identifier: NCT00026884
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
email this page
print this page
bookmark this page
feedback on this page
